- |||||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
New P2 trial: A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) (clinicaltrials.gov) - May 22, 2012 P2, N=84, Active, not recruiting,
|